Improved survival time trends in Hodgkin's lymphoma - Wikidata - wikimedia - TriplyDB

Improved survival time trends in Hodgkin's lymphoma

Improved survival time trends in Hodgkin's lymphoma

http://www.wikidata.org/entity/Q34676451

about

High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.Long-term follow up of Hodgkin lymphoma.

P2860

Q46879226-36CA5937-CA9D-4A47-ADC9-985175D145D8 Q47329066-B2D48387-4CF1-4C54-89A2-BDEBFF6E91B4 Q55002602-C7C10BC1-2276-49FA-BD80-E89F37E856F0

P2860

Improved survival time trends in Hodgkin's lymphoma

http://www.wikidata.org/entity/Q34676451

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Improved survival time trends in Hodgkin's lymphoma

@ast

Improved survival time trends in Hodgkin's lymphoma

@en

Improved survival time trends in Hodgkin's lymphoma

@nl

type

label

Improved survival time trends in Hodgkin's lymphoma

@ast

Improved survival time trends in Hodgkin's lymphoma

@en

Improved survival time trends in Hodgkin's lymphoma

@nl

prefLabel

Improved survival time trends in Hodgkin's lymphoma

@ast

Improved survival time trends in Hodgkin's lymphoma

@en

Improved survival time trends in Hodgkin's lymphoma

@nl

P1433

Q34676451-E0815499-7D15-4A1E-B199-DDF582F38F6A

P1476

Q34676451-6A4EE668-DC83-49D3-A6D8-7CF6265506A9

P2093

Q34676451-B19192BB-77DE-45AB-94EC-9E7EFA63ACF6

Q34676451-BE444C12-6E04-4598-A903-8EE0DF6CE04D

Q34676451-C697320F-74F5-4E6F-AB4D-AB2552FB24B7

P2860

Q34676451-10831797-A1D2-458C-A03C-3C8776A0BD32

Q34676451-131E68E2-1961-498F-B133-29F63F6F5290

Q34676451-27E709A3-345B-41C3-B03A-AC78393FB1F1

Q34676451-2B67924B-5D76-4F19-BCF2-C40050B4A31C

Q34676451-42EB913E-B3F7-4046-A391-6097174EFBBC

Q34676451-457F3A9A-1EAD-42D4-8AC4-57189D414A92

Q34676451-495736A5-8F74-4F11-BFCA-DE96351F3B13

Q34676451-512B6645-5678-4DF8-A49B-2B3E299A5394

Q34676451-5B1ED6BC-F123-43DD-A9A7-DE201DDA5C5C

Q34676451-659F9A5A-A659-4264-B859-05E5E4CBE56B

P304

Q34676451-8B058D6C-7EB5-4CA3-841A-AA1C8BF158CD

P31

Q34676451-8A949D7F-36B0-472E-BC14-01107109EEE7

P356

Q34676451-D06F80D2-8029-479A-B52C-43B2BDA06DA5

P407

Q34676451-8FA748DC-7A02-4053-AD08-196150096B66

P433

Q34676451-86B2BA37-FB5E-4B4D-A3B4-1966B7E767E7

P478

Q34676451-A96550BD-68A7-40B8-98E8-54927808C879

P50

Q34676451-C3114DF0-4D11-4631-AE5E-E42D0DA42EB7

P577

Q34676451-321F3783-F179-498C-AF36-AB6619D23133

P5875

Q34676451-F8B12D66-7548-40AF-9012-F520DA7D43B8

P698

Q34676451-FF6302DA-26BC-4992-AE4A-E2CB71A2502C

P932

Q34676451-0D7D787F-75A0-448C-89E2-BFD1783988D8

P356

P1433

Cancer Medicine

P1476

Improved survival time trends in Hodgkin's lymphoma

@en

P2093

Andrew Fairchild

http://www.w3.org/2001/XMLSchema#string

Christina H Son

http://www.w3.org/2001/XMLSchema#string

Usama Mahmood

http://www.w3.org/2001/XMLSchema#string

P2860

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease.

Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts.

Management of Hodgkin lymphoma.

The role of FDG PET in the management of lymphoma: what is the evidence base?

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

P304

997-1003

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.655

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299341611

http://www.w3.org/2001/XMLSchema#string

P698

26999817

http://www.w3.org/2001/XMLSchema#string

P932

4924356

http://www.w3.org/2001/XMLSchema#string